Creative Medical Technology Holdings, Inc.

CELZ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-6.0M $-5.5M $-5.3M $-10.1M $19.2M $-36.3M $-8.5M $-13.7M
Depreciation & Amortization $56.0K $56.0K
Depreciation
Amortization $123.3K $110.5K $94.6K $92.1K $92.1K $66.8K $27.0K $21.1K
Stock-Based Compensation $3.5K $36.6K $36.6K $68.7K $595.4K $170.3K $0 $1.9K
Net Cash from Operating Activities $-5.9M $-5.3M $-8.0M $-7.8M $-2.2M $-434.6K $-1.2M $-1.1M
Investing Activities
Capital Expenditures
Business Acquisitions $0 $250.0K
Net Cash from Investing Activities $-50.5K $6.3M $3.4M $-10.1M $0 $-250.0K $0
Financing Activities
Dividends Paid
Stock Repurchases $10.0K $175.0K $271.0K $0
Net Cash from Financing Activities $7.2M $1.5M $-271.0K $15.5M $12.8M $693.9K $997.7K $1.3M
Net Change in Cash $1.3M $2.5M $9.4K $-215.4K $290.4K
Free Cash Flow
← Newer Page 1 of 2 Older →